Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

640 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-07-01

Study Completion Date

2021-07-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Primary Objective:

To demonstrate that Purified Vero Rabies Vaccine - Serum Free Vaccine generation 2 (VRVg-2) was non-inferior to Verorab and Imovax Rabies vaccines when co-administered with human rabies immunoglobulin (HRIG), in terms of proportion of participants achieving a rabies virus neutralizing antibody (RVNA) titer greater than or equal to (\>=) 0.5 international units per milliliter (IU/mL) at Day 28, i.e., 14 days after the fourth vaccine injection.

Secondary Objective:

* To describe the safety profile of VRVg-2 versus Verorab and Imovax Rabies vaccines when co-administered with HRIG, as well as that of VRVg-2, after each vaccine injection.
* To demonstrate that the proportion of participants in the VRVg-2 + HRIG group achieving an RVNA titer \>= 0.5 IU/mL at Day 28 was at least 95 percent (%).
* To describe the immune response induced by VRVg-2 versus Verorab and Imovax Rabies vaccines when co-administered with HRIG, as well as that induced by VRVg-2, at Day 14 (7 days after the third injection), at Day 28 (14 days after the fourth injection) and at Day 42 (14 days after the last injection).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Purified Vero Rabies Vaccine and Rabies Human Diploid Cell Vaccine in a Simulated Rabies Post-exposure Regimen

NCT01877395

Rabies

COMPLETED PHASE2

Study of Purified Vero Rabies Vaccine Serum Free Compared With Reference Purified Vero Rabies Vaccine in Healthy Adults

NCT00948272

Rabies

COMPLETED PHASE2

Immunogenicity and Safety of a Purified Vero Rabies Vaccine

NCT03145766

Rabies Virus

COMPLETED PHASE2

Comparison of Purified Vero Rabies Vaccine, Serum Free With Human Diploid Cell Vaccine in Pre-exposure Use

NCT01784874

Rabies

COMPLETED PHASE2

Purified Vero Rabies Vaccine-Serum Free Compared to Human Diploid Cell Vaccine in a Pre-exposure Prophylaxis Regimen

NCT01930357

Rabies

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study duration per participant was approximately 7 months including: 1 day of screening and vaccination, a total of 5 vaccine injections over a 28-day period, 1 safety-follow up visit at Day 42, 1 safety follow-up/end of study visit at Day 56 and a 6-month safety follow-up call after last vaccine administration.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rabies (Healthy Volunteers)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The study was divided into 4 groups: groups 1 to 3 (VRVg-2 + HRIG; Verorab + HRIG; Imovax Rabies + HRIG) were modified double-blind and group 4 (VRVg-2 standalone) was open-label.

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Modified double-blind: the participant (or legally acceptable representative) and the Investigator remain unaware of the treatment assignments throughout the study. An unblinded qualified trial staff member administered the appropriate vaccine but was not involved in the immunogenicity and safety evaluations.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1: VRVg-2 + HRIG

Participants received 0.5 milliliters (mL) intramuscular (IM) injection of VRVg-2 formulation on Days 0, 3, 7, 14 and 28 along with HRIG injection at Day 0.

Group Type EXPERIMENTAL

VRVg-2

Intervention Type BIOLOGICAL

Pharmaceutical form: Powder and solvent for suspension for injection;

Route of administration: IM

Rabies immune globulin (human)

Intervention Type BIOLOGICAL

Pharmaceutical form: Solution for injection;

Route of administration: IM

Group 2: Verorab + HRIG

Participants received 0.5 mL IM injection of Verorab on Days 0, 3, 7, 14 and 28 along with HRIG injection at Day 0.

Group Type ACTIVE_COMPARATOR

Purified Inactivated Rabies Vaccine

Intervention Type BIOLOGICAL

Pharmaceutical form: Powder and solvent for suspension for injection;

Route of administration: IM

Rabies immune globulin (human)

Intervention Type BIOLOGICAL

Pharmaceutical form: Solution for injection;

Route of administration: IM

Group 3: Imovax Rabies + HRIG

Participants received 1 mL IM injection of Imovax Rabies on Days 0, 3, 7, 14 and 28 along with HRIG injection at Day 0.

Group Type ACTIVE_COMPARATOR

Human Diploid Cell Vaccine (HDCV)

Intervention Type BIOLOGICAL

Pharmaceutical form: Powder and solvent for suspension for injection;

Route of administration: IM

Rabies immune globulin (human)

Intervention Type BIOLOGICAL

Pharmaceutical form: Solution for injection;

Route of administration: IM

Group 4: VRVg-2

Participants received 0.5 mL IM injection of VRVg-2 formulation on Days 0, 3, 7, 14 and 28.

Group Type EXPERIMENTAL

VRVg-2

Intervention Type BIOLOGICAL

Pharmaceutical form: Powder and solvent for suspension for injection;

Route of administration: IM

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VRVg-2

Pharmaceutical form: Powder and solvent for suspension for injection;

Route of administration: IM

Intervention Type BIOLOGICAL

Purified Inactivated Rabies Vaccine

Pharmaceutical form: Powder and solvent for suspension for injection;

Route of administration: IM

Intervention Type BIOLOGICAL

Human Diploid Cell Vaccine (HDCV)

Pharmaceutical form: Powder and solvent for suspension for injection;

Route of administration: IM

Intervention Type BIOLOGICAL

Rabies immune globulin (human)

Pharmaceutical form: Solution for injection;

Route of administration: IM

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Verorab® IMOVAX® Rabies IMOGAM® Rabies-HT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men or women aged \>=18 years on the day of inclusion (\>= 18 years means from the day of the 18th birthday onwards, with no upper age limit).
* Able to attend all scheduled visits and to comply with all trial procedures.
* Body Mass Index (BMI): 18.5 kilograms per square meter (kg/m\^2) less than or equal to (\<=) BMI \<=30 kg/m\^2.

Exclusion Criteria

* Pregnant, or lactating, or of childbearing potential and not using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination until at least 4 weeks after the last vaccination. To be considered of non-childbearing potential, a female must be post-menopausal for at least 1 year, or surgically sterile.
* Participation at the time of study enrollment or, planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure.
* Receipt of any vaccine in the 4 weeks (28 days) preceding the first trial vaccination or planned receipt of any vaccine prior to Visit 7.
* Previous vaccination against rabies (in pre- or post-exposure regimen) with either the trial vaccines or another vaccine.
* Receipt of immune globulins, blood or blood-derived products in the past 3 months.
* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
* At high risk for rabies exposure during the trial (veterinarians and their staff, animal handlers, rabies researchers, and certain laboratory workers, persons whose activities bring them into frequent contact with rabies virus or potentially rabid bats, raccoons, skunks, cats, dogs, or other species at risk for having rabies, people travelling where rabies was enzootic).
* Known systemic hypersensitivity to any of the vaccine or HRIG components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances.
* Self-reported thrombocytopenia, contraindicating IM vaccination.
* Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination.
* Current alcohol or substance abuse that, in the opinion of the investigator, might interfere with the trial conduct of completion.
* Chronic illness that, in the opinion of the investigator, was at a stage where it might interfere with trial conduct or completion.
* Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature \>=38.0 degree Celsius). A prospective participant should not be included in the study until the condition had resolved or the febrile event had subsided.
* Personal history of Guillain-Barré syndrome.
* Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes